To report toxicity and efficacy outcome of moderately hypofractionated image-guided external-beam radiotherapy in a large series of patients treated for prostate cancer (PCa). Between 10/2006 and 12/2015, 572 T1-T3N0M0 PCa patients received 70.2 Gy in 26 fractions at 2.7 Gy/fraction: 344 patients (60%) with three-dimensional conformal radiotherapy (3D-CRT) and 228 (40%) with intensity-modulated radiotherapy (IMRT). Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria and Houston definition (nadir + 2) were used for toxicity and biochemical failure evaluation, respectively. Median age was 74 years (interquartile range 69–77). Compared with 3D-CRT, in IMRT group more high-risk patients (29% vs 18%; P = 0.002) and more high-volume target (75% vs 60%; P < 0.001) were included. Acute gastro-intestinal (GI) toxicity G > 1 were registered in 8% and in 11% IMRT and 3D-CRT patients, respectively, whereas late GI G > 1 were observed in 2% and 16% IMRT and 3D-CRT patients, respectively. Acute genito-urinary (GU) toxicity G > 1 were registered in 26% and 40% IMRT and 3D-CRT patients, respectively, whereas late GU G > 1 occurred in 5% IMRT and 15% 3D-CRT patients. Multivariate proportional hazard Cox models confirmed significantly greater risk of late toxicity with 3D-CRT compared to IMRT for GU > 1 (P = 0.004) and for GI > 1 (P < 0.001). With a median 4-year follow-up, overall survival (OS), clinical progression-free survival (cPFS) and biochemical PFS (bPFS) for the whole series were 91%, 92% and 91%, respectively. cPFS and bPFS were significantly different by risk groups. Multivariate Cox models for bPFS and cPFS showed no difference between irradiation techniques and a significant impact of risk group and initial PSA. Moderately hypofractionated radiotherapy is a viable treatment option for localized PCa with excellent tumour control and satisfactory toxicity profile. IMRT seems associated with a reduction in toxicity, whereas tumour control was equal between IMRT and 3D-CRT patients and depended mainly on the risk category.
Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer / B.A. Jereczek-Fossa, A. Maucieri, G. Marvaso, G.S. Gandini, C. Fodor, D. Zerini, G. Riva, O. Alessandro, A. Surgo, S. Volpe, G. Fanetti, S. Arculeo, M.A. Zerella, S. Parisi, P. Maisonneuve, A. Vavassori, F. Cattani, R. Cambria, C. Garibaldi, A. Starzyńska, G. Musi, O. De Cobelli, M. Ferro, F. Nolè, D. Ciardo, R. Orecchia. - In: MEDICAL ONCOLOGY. - ISSN 1357-0560. - 36:1(2019), pp. 9.1-9.9.
|Titolo:||Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer|
MARVASO, GIULIA (Corresponding)
|Parole Chiave:||Dose escalation; Hypofractionation; Image-guided radiotherapy; Prostate cancer; Adult; Aged; Aged, 80 and over; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Prostatic Neoplasms; Radiation Dose Hypofractionation; Radiation Injuries; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Retrospective Studies; Hematology; Oncology; Cancer Research|
|Settore Scientifico Disciplinare:||Settore MED/24 - Urologia|
|Data di pubblicazione:||2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1007/s12032-018-1233-1|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|Jereczek-Fossa2018_Article_ImpactOfImageGuidanceOnToxicit.pdf||Publisher's version/PDF||Administrator Richiedi una copia|